© ISTOCK.COM/STROBLOWSKI
When cancer researcher Ben Bonavida accepted a visiting graduate student from Japan into his lab at the University of California, Los Angeles (UCLA) just over a decade ago, he treated Eriko Suzuki like every other student he had supervised for the past 30 years. “I met with her regularly,” Bonavida recalls. “We went over her data, she showed me all the Westerns, all the experiments.” After months spent working on the cancer therapeutic rituximab’s mechanism of action, “she presented her findings to me and the other collaborators in the lab, and based on that we published a paper in Oncogene.”
Appearing in 2007, the paper accrued nearly 40 citations over the next seven years. But in April 2014, the study gained a less favorable mention ...